In a recent investigation involving a rodent model of liver cancer, the HSYA treatment proved effective in diminishing the levels of crucial immune environment regulators, such as forkhead box protein P3 (FOXP3) and retinoic acid receptor-related orphan receptor gamma-t (RoRγt) proteins, and lowering the number of regulatory T cells in the spleen at certain dosages (56). The gene discussed is FOXP3; the disease is liver cancer.